Triumph Capital Management »

Bioxcel Therapeutics shares owned by Triumph Capital Management

Quarter-by-quarter ownership of Bioxcel Therapeutics (BTAI) shares owned by Triumph Capital Management from 13F filings

Historical chart of Triumph Capital Management investment in Bioxcel Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Bioxcel Therapeutics held by Triumph Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bioxcel Therapeutics by Triumph Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $3 1 3.00

More positions owned by Triumph Capital Management

First Trust Enhanced Short Maturity Etf Etf (FTSM)
First Trust Smith Opportunistic Fixed Income Etf Etf (FIXD)
First Trust Rising Dividend Achievers Etf Etf (RDVY)
First Trust Capital Strength Etf Etf (FTCS)
Vanguard Total Bond Market Etf Etf (BND)
First Trust Smid Cap Rising Dividend Achievers Etf Etf (SDVY)
Spdr S&p 500 Etf Trust Etf (SPY)
Jpmorgan Ultra-short Income Etf Etf (JPST)
Invesco Qqq Trust Series I Etf (QQQ)
Ishares Core S&p 500 Etf Etf (IVV)
First Trust Morningstar Dividend Leaders Index Fund Etf (FDL)
First Trust Low Duration Opportunities Etf Etf (LMBS)
First Trust Large Cap Core Alphadex Fund Etf (FEX)
Nvidia Corporation Stock (NVDA)
Ishares Russell Midcap Etf Etf (IWR)

View all positions for Triumph Capital Management

Top funds holding Bioxcel Therapeutics

Millennium Management
Oaktree Capital Management
FMR
Vanguard Group
Geode Capital Management
XTX Topco
BlackRock
State Street Corporation
UBS Group
Oaktree Fund Advisors
Northern Trust
Jones Financial Companies, L.L
HighTower Advisors
Foundations Investment Advisors
SLT Holdings

View all funds holding Bioxcel Therapeutics